Medicines Co. (MDCO) Receives $132M HHS Grant, Enters Partnership with BARDA for Gram-Negative Infections Antibiotics
- S&P 500 closes higher to secure strongest Q1 since 2019
- UBS sees 5 warnings signals on semiconductor chip stocks
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- Reddit (RDDT) stock continues to slide as short-sellers eye stock
- Estée Lauder (EL) climbs as BofA upgrades to Buy on profit recovery expectations
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- Discover Financial Services (DFS) Announces CEO Resignation
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Timken (TKR) Appoints Tarak Mehta as New CEO
The Medicines Company Awarded up to $132 Million to Develop Portfolio of New Antibiotics Targeting Drug-Resistant Infections under Strategic Partnership with BARDA
September 21, 2016 7:30 AM EDTProvides up to $132 million to support development of the Companys leading pipeline of antibiotics targeting drug-resistant bacteria, including the ongoing development of CARBAVANCE® (meropenem-vaborbactam)
First portfolio-based strategic partnership between the Biomedical Advanced Research and Development Authority (BARDA) and a U.S. headquartered company
Strategic partnership evidences the leadership position of The Medicines Companys Infectious Disease Business, its proven track record of innovative research and development and the strength of its growing commercial capabilities
Builds on the success of the Companys existing agreement with BARDA... More